These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 2191588)

  • 1. Spironolactone versus nifedipine in essential hypertension.
    Henry M; Wehrlen M; Pelletier B; Capron MH
    Am J Cardiol; 1990 Jun; 65(23):36K-38K. PubMed ID: 2191588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind, controlled, multicenter, randomized study comparing the antihypertensive effectiveness and tolerance of a daily dose of two nifedipine formulations: nifedipine microgranules versus nifedipine osmotic pump.
    de Roa ER; Botero R; Octavio JA; Berrizbeitia ML; Mayorca E; Castro P; Miranda R; Valecillo E; Aroca G; Aza G; González M
    Am J Ther; 2007; 14(2):140-6. PubMed ID: 17414581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atenolol plus nifedipine for mild to moderate systemic hypertension after fixed doses of either agent alone.
    Daniels AR; Opie LH
    Am J Cardiol; 1986 Apr; 57(11):965-70. PubMed ID: 3515899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A randomized double-blind therapeutic trial of enalapril versus timed-release nifedipine in mild to moderate essential hypertension].
    Artigou JY; Benichou M; Berland J; Fressinaud P; Grollier G; Guéret P; Nguyen Cong Duc L
    Presse Med; 1990 Jan 6-13; 19(1):13-6. PubMed ID: 2137218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nifedipine controlled-release 40 mg b.i.d. in Japanese patients with essential hypertension who responded insufficiently to nifedipine controlled-release 40 mg q.d.: a phase III, randomized, double-blind and parallel-group study.
    Shimamoto K; Hasebe N; Ito S; Kario K; Kimura K; Dohi Y; Kawano Y; Rakugi H; Horiuchi M; Imaizumi T; Ohya Y
    Hypertens Res; 2014 Jan; 37(1):69-75. PubMed ID: 23945965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial.
    Václavík J; Sedlák R; Plachy M; Navrátil K; Plásek J; Jarkovsky J; Václavík T; Husár R; Kociánová E; Táborsky M
    Hypertension; 2011 Jun; 57(6):1069-75. PubMed ID: 21536989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atenolol and sustained release nifedipine alone and in combination in hypertension. A randomised, double-blind, crossover study.
    Anderton JL; Vallance BD; Stanley NN; Crowe PF; Mittra B; Perks WH
    Drugs; 1988; 35 Suppl 4():22-6. PubMed ID: 3288467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lisinopril versus slow-release nifedipine in the treatment of mild to moderate hypertension: a multicentre study. The Cooperative Study Group.
    Witchitz S; Serradimigni A
    J Hum Hypertens; 1989 Jun; 3 Suppl 1():29-33. PubMed ID: 2550643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood pressure control by the nifedipine GITS-telmisartan combination in patients at high cardiovascular risk: the TALENT study.
    Mancia G; Parati G; Bilo G; Choi J; Kilama MO; Ruilope LM;
    J Hypertens; 2011 Mar; 29(3):600-9. PubMed ID: 21252701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension.
    Messerli FH; Oparil S; Feng Z
    Am J Cardiol; 2000 Dec; 86(11):1182-7. PubMed ID: 11090788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of nifedipine GITS and hydrochlorothiazide in the management of elderly patients with stage I-III diastolic hypertension.
    Dey HM; Soufer R; Hoffer P; Wackers FJ; Black HR
    Am J Hypertens; 1996 Jun; 9(6):598-606. PubMed ID: 8783785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and tolerability of nifedipine (NIF) and nisoldipine (NIS) both alone and combined with a beta-blocker in patients with essential hypertension: a multicenter, parallel-group study.
    Rosenfeld JB; Zabludowski J
    J Clin Pharmacol; 1989 Nov; 29(11):1013-6. PubMed ID: 2574728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of extended-release felodipine and extended-release nifedipine in patients with mild-to-moderate essential hypertension.
    Fagan TC; Haggert BE; Liss C
    Clin Ther; 1994; 16(4):634-46. PubMed ID: 7982251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of effects of controlled onset extended release verapamil at bedtime and nifedipine gastrointestinal therapeutic system on arising on early morning blood pressure, heart rate, and the heart rate-blood pressure product.
    White WB; Black HR; Weber MA; Elliott WJ; Bryzinski B; Fakouhi TD
    Am J Cardiol; 1998 Feb; 81(4):424-31. PubMed ID: 9485131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety and efficacy of once-daily nifedipine coat-core in combination with atenolol in hypertensive patients. Adalat CC Cooperative Study Group.
    Mac Carthy EP; Pettis PP; Gibson L; Schwartz L; Feig PU
    Clin Ther; 1993; 15(6):976-87. PubMed ID: 8111817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy and safety of enalapril and sustained-release nifedipine in patients with mild to moderate hypertension. The Enalapril vs Nifedipine French Study Group.
    Gueret P; Artigou JY; Benichou M; Berland J; Fressinaud P; Grollier G; Nguyen CD
    Drugs; 1990; 39 Suppl 2():67-72. PubMed ID: 2188826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Labetalol and nifedipine in the management of essential hypertension.
    Prasad NK
    J Indian Med Assoc; 1990 Jul; 88(7):188-9. PubMed ID: 2266262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spironolactone and altizide versus converting enzyme inhibitor (enalapril).
    Grünfeld JP; Wehrlen M; Pelletier B; Capron MH
    Am J Cardiol; 1990 Jun; 65(23):28K-32K. PubMed ID: 2191586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antihypertensive efficacy of a slow release nifedipine tablet formulation given once daily in patients with mild to moderate hypertension. A placebo-controlled, double-blind parallel-group trial.
    Harder S; Rietbrock S; Thürmann P
    Arzneimittelforschung; 1994 Feb; 44(2):133-6. PubMed ID: 8147945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nifedipine and atenolol singly and combined for treatment of essential hypertension: comparative multicentre study in general practice in the United Kingdom. Nifedipine-Atenolol Study Review Committee.
    Nifedipine-Atenolol Study Review Committee
    Br Med J (Clin Res Ed); 1988 Feb; 296(6620):468-72. PubMed ID: 2894883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.